Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Herpesvirus entry mediator regulates hypoxia-inducible factor–1α and erythropoiesis in mice
Yukimi Sakoda, … , Lieping Chen, Koji Tamada
Yukimi Sakoda, … , Lieping Chen, Koji Tamada
Published November 14, 2011
Citation Information: J Clin Invest. 2011;121(12):4810-4819. https://doi.org/10.1172/JCI57332.
View: Text | PDF
Research Article Hematology

Herpesvirus entry mediator regulates hypoxia-inducible factor–1α and erythropoiesis in mice

  • Text
  • PDF
Abstract

Erythropoiesis, the production of red blood cells, must be tightly controlled to ensure adequate oxygen delivery to tissues without causing thrombosis or stroke. Control of physiologic and pathologic erythropoiesis is dependent predominantly on erythropoietin (EPO), the expression of which is regulated by hypoxia-inducible factor (HIF) activity in response to low oxygen tension. Accumulating evidence indicates that oxygen-independent mediators, including inflammatory stimuli, cytokines, and growth factors, also upregulate HIF activity, but it is unclear whether these signals also result in EPO production and erythropoiesis in vivo. Here, we found that signaling through herpesvirus entry mediator (HVEM), a molecule of the TNF receptor superfamily, promoted HIF-1α activity in the kidney and subsequently facilitated renal Epo production and erythropoiesis in vivo under normoxic conditions. This Epo upregulation was mediated by increased production of NO by renal macrophages. Hvem-deficient mice displayed impaired Epo expression and aggravated anemia in response to erythropoietic stress. These data reveal that HVEM signaling functions to promote HIF-1α activity and Epo production, and thus to regulate erythropoiesis. Furthermore, our findings suggest that this molecular mechanism could represent a therapeutic target for Epo-responsive diseases, including anemia.

Authors

Yukimi Sakoda, Sudarshan Anand, Yuming Zhao, Jang-June Park, Yingjia Liu, Atsuo Kuramasu, Nico van Rooijen, Ling Chen, Scott E. Strome, Wayne W. Hancock, Lieping Chen, Koji Tamada

×

Figure 1

Administration of the anti-HVEM mAb HM3.30 induces erythropoiesis in mice.

Options: View larger image (or click on image) Download as PowerPoint
Administration of the anti-HVEM mAb HM3.30 induces erythropoiesis in mic...
(A–D) WT C57BL/6 mice were injected i.p. with 150 μg control Ig or HM3.30 and examined on day 4. (A) Gross appearance of the treated spleen. (B) Absolute numbers of the indicated cell populations per spleen in mice treated with control Ig or HM3.30, examined by flow cytometry (n ≥ 5). *P < 0.01. (C) Percent basophilic (Ter119+CD71hi), polychromatophilic (Ter119+CD71med), and orthochromatic (Ter119+CD71lo) erythroblasts in spleen, examined by flow cytometry. (D) In addition to Ab injection, mice were treated i.p. with 100 μg BrdU every 24 hours. Spleen cells were analyzed for Ter119 and BrdU staining by flow cytometry. Numbers denote the percentage of cells in the respective gates. (E) Absolute number of Ter119+CD45– erythrocytes in the spleen of mice treated with control Ig or HM3.30 as in A–C (n = 3 each). Data represent mean ± SD.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts